Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum β-lactamase-producing Enterobacteriaceae

Clin Microbiol Infect. 2023 Jul;29(7):823-825. doi: 10.1016/j.cmi.2023.03.022. Epub 2023 Mar 22.

Authors

Romain Gueneau¹, Benoit Henry²

Affiliations

¹ AP-HP, Hôpital Bicêtre, Service des maladies Infectieuses, Université Paris-Saclay, Le Kremlin-Bicêtre, France. Electronic address: romain.gueneau21@gmail.com.
² AP-HP, Hôpital Bicêtre, Service des maladies Infectieuses, Université Paris-Saclay, Le Kremlin-Bicêtre, France.

PMID: 36958687
DOI: 10.1016/j.cmi.2023.03.022

No abstract available

Keywords: Antimicrobial resistance; Carbapenem sparing; ESBL; Kidney transplant recipient; Pyelonephritis.

MeSH terms

Carbapenems* / therapeutic use
Enterobacteriaceae
Humans
Piperacillin, Tazobactam Drug Combination / therapeutic use
Pyelonephritis* / drug therapy
beta-Lactamases

Substances

Carbapenems
Piperacillin, Tazobactam Drug Combination
beta-Lactamases